spec sheet5 rows
AQW051 was Novartis's alpha7 nicotinic acetylcholine receptor partial agonist, developed alongside ABT-126, TC-5619, and encenicline in the industry-wide push to translate the alpha7 receptor's role in hippocampal and prefrontal circuits into a working schizophrenia cognition drug. Novartis took an unusually mechanistic approach to testing it, using functional MRI in a randomized crossover trial to watch how the drug changed brain activation during working-memory and episodic-memory tasks in people with chronic, stable schizophrenia, rather than relying on behavioral scores alone. The imaging trial found AQW051 did alter neuronal activity in prefrontal and hippocampal regions, but it did not translate into a consistent cognitive benefit, and in smokers at higher doses working memory performance seemed to get worse rather than better. Combined with the broader wave of alpha7 agonist failures across the industry, Novartis did not carry AQW051 forward into larger confirmatory trials.
- measurably altered prefrontal and hippocampal brain activation on fMRI during memory tasks
- well tolerated with an acceptable safety profile in the trial
- tested with an unusually rigorous imaging-based trial design
- no consistent improvement in working memory or episodic memory task performance
- appeared to worsen working memory performance in smokers at higher doses
- AQW051's trial found it could actually worsen working memory in smokers at high doses, a mirror image of the pattern seen with ABT-126, where nonsmokers benefited but smokers got nothing.
Mechanism
Selective alpha7 receptor partial ; evaluated via functional MRI for its effects on prefrontal and hippocampal activation during working-memory and episodic-memory tasks.
Safetyrisks and cautions, not medical advice
One hundred and eighty healthy volunteers went through three placebo-controlled Phase 1 studies without a single serious adverse event, every complaint mild or moderate, at single doses up to 200 mg and daily dosing up to 75 mg. The 28-day Parkinson's trial listed dyskinesia, fatigue, nausea and falls as the commonest events, and the schizophrenia imaging study reported an acceptable profile. That is a decent short-term record. Nothing beyond a month of dosing was ever tested, and the programme closed for lack of benefit, not for a safety finding.
History
Developed by Novartis; a randomized, placebo-controlled crossover fMRI trial (NCT00825539) in chronic schizophrenia patients found altered prefrontal and hippocampal brain activation but no consistent cognitive benefit, and the compound was not advanced into larger trials.
Subjective profileweighing the evidence above
One of the more methodologically careful attempts at the alpha7 hypothesis, using brain imaging instead of just behavioral scores, and it still didn't find a usable cognitive benefit.
Resources
This entry is here for reference.
Research
- 1.Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial
- 2.AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.
2 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What made the AQW051 trial unusual?
Instead of relying only on cognitive test scores, Novartis used functional MRI to directly observe how the drug changed brain activation in memory-related regions during task performance, a more mechanistic approach than most schizophrenia cognition trials of the era.
Did brain imaging showing changed activation mean the drug worked?
No. AQW051 measurably altered activation patterns in prefrontal and hippocampal regions, but that neural change did not reliably translate into better task performance, which is exactly why it wasn't developed further.
Limitations of the evidence
- not advanced past this exploratory trial stage
Adverse effects
- no consistent improvement in working memory or episodic memory task performance
- appeared to worsen working memory performance in smokers at higher doses